Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Construction Of An Immune Gene Expression Meta Signature To Assess The Prognostic Risk Of Colorectal Cancer Patients.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Construction Of An Immune Gene Expression Meta Signature To Assess The Prognostic Risk Of Colorectal Cancer Patients.

Related Experiment Video

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

Construction of an immune gene expression meta signature to assess the prognostic risk of colorectal cancer patients.

Carlos Orozco-Castaño¹, Alejandro Mejia-Garcia², Yina Zambrano³

¹Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología (INC), Bogotá, Colombia; Grupo de Apoyo y Seguimiento para la Investigación GASPI, Instituto Nacional de Cancerología (INC), Bogotá, Colombia.

Advances in Genetics

|October 13, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed a new immune gene signature to predict colorectal cancer (CRC) patient outcomes, aiding personalized treatment decisions for better prognosis and management.

Keywords:

Bioinformatics Colorectal cancer (CRC)Gene expression signatures Prognostic model

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Area of Science:

Oncology
Immunogenomics
Bioinformatics

Background:

Colorectal cancer (CRC) treatments, including immunotherapy, benefit only a subset of patients.
Predictive biomarkers are needed to guide treatment decisions and improve patient outcomes in CRC.

Purpose of the Study:

To develop a prognostic biomarker based on immune-related genes for colorectal cancer (CRC).
To predict patient outcomes and aid in treatment decision-making for CRC.

Main Methods:

Utilized The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets for CRC patient cohorts.
Employed Cox regression, LASSO penalization, and differential expression analysis to identify prognostic immune genes.
Conducted Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses for functional insights and validated immune cell infiltration.

Main Results:

Identified a novel immune-related gene signature with significant prognostic potential in CRC.
The developed risk prediction model effectively stratified patients into high-risk and low-risk groups with distinct survival outcomes.
High-risk group showed enrichment in pro-oncogenic pathways and increased immunosuppressive immune cell infiltration.

Conclusions:

The novel immune gene signature serves as a reliable prognostic indicator for colorectal cancer (CRC) patient survival.
This biomarker can facilitate personalized management strategies, improving treatment efficacy and patient prognosis.
Further research can explore the therapeutic targeting of identified immune pathways in CRC.